Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database

CONCLUSIONS: Thyroiditis is common, often asymptomatic, and is more prevalent in patients treated with combinations of nivolumab and PD-L1 inhibitors, and in patients with renal cell carcinoma. Thyroiditis was associated with a trend for a survival benefit, particularly in patients with renal cell carcinoma.PMID:34379562 | DOI:10.1080/0284186X.2021.1958006

Source: Acta Oncologica - August 11, 2021 Category: Cancer & Oncology Authors: Ruth Percik Yair Liel Damien Urban Jair Bar Eytan Ben-Ami Muhammad Abu Tailakh Source Type: research